CSL Limited
CMXHF
Other OTC86.80
USD
+3.62
- -
CSL Limited
CMXHF
(Other OTC)
Recent
price
86.80
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- CSL Limited is an Australian global biotechnology company specializing in the research, development, manufacture, and marketing of biopharmaceutical products and vaccines. The company operates through three main segments: CSL Behring, CSL Seqirus, and CSL Vifor. CSL Behring produces plasma-derived therapies, gene therapies, and recombinant products targeting rare and serious diseases including immunodeficiencies, hemophilia, and hereditary angioedema. CSL Seqirus focuses on influenza-related products and pandemic preparedness services, offering vaccines such as adjuvanted and cell-based flu vaccines. CSL Vifor develops and markets treatments primarily in iron deficiency, nephrology, and other specialty areas. CSL also operates plasma collection networks globally, with more than 325 centers across the United States, Europe, and China. Founded in 1916 and headquartered in Melbourne, Australia, CSL is active in numerous countries including the United States, Germany, the United Kingdom, Switzerland, and China. Recent major changes include the 2022 acquisition of Swiss drugmaker Vifor Pharma, which expanded CSL’s portfolio into iron deficiency and nephrology treatments. The company unified its divisions under the CSL brand name, consolidating its subsidiaries as CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor. In 2024 and 2025, CSL launched or advanced key products such as HEMGENIX, a one-time gene therapy for hemophilia B, and Garadacimab, a monoclonal antibody for hereditary angioedema. CSL also announced a $1.5 billion investment in US drug manufacturing facilities to enhance production capabilities. Moreover, in 2025, CSL strategically acquired EdgeConnect, an internet connectivity specialist, to strengthen its IoT capabilities and expand into demanding sectors. The company continues to invest heavily in R&D with a focus on innovation in plasma therapies, vaccines, and gene therapies, maintaining a leadership position in global biotechnology markets. CSL services includes plasma-derived immunoglobulins (Privigen, Hizentra), coagulation factors (Idelvion), vaccines for influenza (Fluad, Flucelvax), and therapies for iron deficiency and nephrology. Its products and services target hospitals, healthcare providers, government pandemic programs, and specialty markets worldwide. CSL’s integrated operations and pipeline innovations position it as a key player in rare disease treatments, plasma biotherapeutics, and vaccine manufacturing, with a commitment to expanding access and advancing medical solutions globally. The company employs over 32,000 people and reported sales revenue exceeding AUD 23 billion in 2025.
CSL Plunges 22% After Cutting Outlook And Flagging $5 Billion Impairments